-
AbbVie's JAK inhibitor Rinvoq, Phase III clinically demonstrated the potential for the treatment of endeavoid dermatitis.
Time of Update: 2020-10-02
In the Phase III Measure Up 1 study, patients treated with 15 mg or 30 mg doses of Rinvoq improved their eczema area severity index (EASI 75) by 75 percent at the 16th week, respectively, compared with 16 percent in the placebo group.
-
J Rheumatol: essential lesions of the air and lungs of primary dryness syndrome.
Time of Update: 2020-10-02
The study aimed to assess the progression of pulmonary function and chronic obstructive pulmonary disease (COPD) in patients with primary dryness syndrome (pSS), as well as the association between lung function, imaging performance, respiratory symptoms and pSS clinical characteristics, taking smoking into account.
-
A list of recent research advances in the journal Nature for the new coronavirus SARS-CoV-2/COVID-19 (No. 4)
Time of Update: 2020-09-30
1.Nature: Revealing the structural mechanism of SARS-CoV-2 hedgehog protein binding human ACE2 receptor doi:10.1038/s41586-020-2772 In a new study, researchers from the Francis-Crick Institute in the United Kingdom found that the prickly protein (S protein) on the surface of the SARS-CoV-2 coronavirus can take at least ten different structural states when in contact with the human virus-like ACE2.
-
PNAS: Variable targets help the immune system fine-tune antibodies.
Time of Update: 2020-09-29
the ability to produce antibodies that bind effectively to external sources but not to their own molecules are a major challenge in vaccine development, the researchers said.
-
Cell: Single dose of ChAd vaccine protects the upper and lower respiratory tracts from SARS-CoV-2 infection.
Time of Update: 2020-09-29
AUGUST 26, 2020 /--- In a new study, researchers at the University of Washington's St. Louis School of Medicine have developed a vaccine for the SARS-CoV-2 virus, known as ChAd, that can be effectively prevented in mice sensitive to the new coronavirus through a nose injection.
-
Immunity: Identification of early stem cells in human bone marrow that produce nexual granulocytes.
Time of Update: 2020-09-29
, in a new study, researchers from the La Hoya Institute of Immunology (LJI) tracked rare stem cells in human bone marrow that produce neuficial granulocytes.
-
PLoS Pathog: The multiple sclerosis drug Fingommod blocks hiv infection and transmission in human immune cells.
Time of Update: 2020-09-29
AUGUST 22, 2020 /--- In a new study, Rachel Resop, a postdoctoral researcher at George Washington University in the United States, and Alberto Bosque, an assistant professor, and colleagues found that Fingolimod (FTY720), an immunomodulative drug approved for the treatment of multiple sclerosis, can block the infection and transmission of HIV in human immune cells.
-
Journal of Science: Tumor-targeted CD28 dual-specific antibodies enhance the anti-tumor effect of PD-1 immunotherapy.
Time of Update: 2020-09-29
Janelle Waite and Dimitris Skokos, members of a larger Regeneron research team, are testing whether a class of co-irritating CD28 dual-specific antibodies enhances anti-tumor activity.
year, French scientists raised the issue of rotavirus vaccines that can be used to overcome cancer cell resistance to immune checkpoint blocking immunotherapy.
-
Cell: Discover the new metabolic immuno checkpoint IL4I1! It activates aromatic hydrocarbons and promotes tumor progress.
Time of Update: 2020-09-29
results were published online August 19, 2020 in the journal Cell under the title "IL4I1 Is a Metabolic Immune Checkpoint that Activates the AHR and Promotes Tumor Progress." author of the paper is Christiane Opitz of the German Cancer Research Centre.
-
The Food and Drug Administration approved the new coronary plasma therapy, saying its benefits outweigh the risks.
Time of Update: 2020-09-29
, Trump reportedly said at a news conference the same day, "This (plasma therapy) is a powerful treatment, from the blood of recovering patients to convert very strong antibodies to help infected people fight (the new coronavirus).
-
Why is the health of the young population more vulnerable?
Time of Update: 2020-09-29
doi:10.1001/jamanetworkopen.2019.9261 In a recent study published in the international journal JAMA Network Open, scientists from Case Western Reserve University analyzed data on disease rates across the country from 2000 to 2016 and found that Obesity-related cancers (OACs, obesity-associated cancers) are being transferred to the younger population, generally with higher rates of diagnosis among people over 65 years of age, most notably in non-Hispanic black and Hispanic women and men, and in some cases by 200-400 percent.
-
Fat crystals cause chronic inflammation.
Time of Update: 2020-09-29
AUGUST 26, 2020 /--- According to a recent study published in the journal Autophagy, researchers from the University of Bonn have found that congenital disorders in fat metabolism cause chronic inflammation of the immune system.
-
Breakthrough drugs for cystic fibrosis (CF)! Vertex's innovative triple therapy Kaftrio has been approved by the European Union to treat up to 90% of patients!
Time of Update: 2020-09-29
announced recently that the European Commission (EC) has approved a 150mg joint drug treatment programme for Kaftrio (ivacaftor/tezacaftor/elexacaftor) and Kalydeco (ivacaftor) for the treatment of 12 years of age In CF patients, specifically in patients with an F508del mutation and a minimal functional mutation (F/MF) in the cystic fibrosis transfilm conductivity regulator (CFTR) gene, or in patients with 2 F508del mutations (F/F).
-
Nat Med: Preliminary clinical trial results show that the combination of Pym monoantas and BL-8040 can double the rate of treatment response in pancreatic cancer patients.
Time of Update: 2020-09-29
, co-author of the study and a researcher at the HonorHealth Institute, said, "Meaningful tumor reduction rates are 32 percent, twice as high as for pancreatic cancer patients treated with traditional chemotherapy." although the study is small, these preliminary results are encouraging and we hope to conduct a larger clinical trial to see if the treatment responds better and is better than traditional therapies, " he said.
-
Kidney transplant new drug! The new IgG antibody cutting enzyme Idefirix has been approved by the European Union for use in highly sensitive kidney transplant patients!
Time of Update: 2020-09-29
, the company announced that the European Commission (EC) has conditions to approve the new IgG antibody degradation enzyme Idefirix (imlifidase) for highly sensitive kidney transplant patients.
clinical data show that imlifidase can quickly and specificly cut IgG antibodies, successfully enabling these patients to carry out life-saving kidney transplants.
-
How do scientists look for biomarkers that indicate a variety of human diseases?
Time of Update: 2020-09-29
However, it may be too late for autoantibodies to be detected to prevent the occurrence and development of diabetes; JCI Insights: New biomarkers can diagnose severe renal allergic reactions doi:10.1172/jci.insight.127456 In a study published in the international journal JCI Insights, medical researchers from Johns Hopkins University identified two protein biomarkers in urine that could one day be used to better diagnose acute interstitrinitis (AIN).
-
Bio Valley recommendation: August must-see heavyweight study Top10.
Time of Update: 2020-09-29
!-- webeditor: page title" -- In a blink of an eye August is drawing to a close, what are the highlights of this month worthy of further study? Based on the type, heat, and field of study of this mont
-
Scientists have made new achievements in the field of EB virus research!
Time of Update: 2020-09-29
In !-- article, we have compiled a number of important research results to learn from recent scientists in the field of EB virus research! Photo credit: Li, Z., et al. Cell Res (2020). doi:10.1038/s41
-
Heavy article interpretation of recent years in the field of embryonic stem cell research new achievements!
Time of Update: 2020-09-29
Doi:10.1038/s41586-020-2383-9 In a recent study published in the international journal Nature, scientists from Cambridge University and other institutions developed a new model to study the early stages of human development using embryonic stem cells.
-
JAMA sub-journal: Does high antibody concentration equal to high protection?
Time of Update: 2020-09-29
the study found that antibody concentrations in older and male patients were significantly higher than in younger and female patients, while symptoms in older and male patients tended to be more severe, meaning that high concentrations of meso-antibodies were not necessarily effective against the new coronavirus and provided new insights into the sources of protection against the new coronary vaccine.
